SCHEMBL139274

SCHEMBL139274

COC(=O)c1cc(OC)ncc1-c1nc(Br)cc(C(=O)OC)c1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 4/20 0.39
NNMT P40261 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 5/20 0.37
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP3A4 P08684 1/20 0.34
PKM P14618 1/20 0.34
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
CFTR P13569 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL139273 0.81 MKNK1 (0.45) L3MBTL1KDM4ENNMTKMT2AMEN1
SCHEMBL141017 0.81 PLA2G2A (0.50) KDM4ECYP1A2CYP2C19SMN1; SMN2CYP2C9
SCHEMBL139120 0.78 AKT1 (0.41) KDM4EKMT2AMEN1ALDH1A1TSHR
SCHEMBL2472898 0.78 L3MBTL1 (0.41) L3MBTL1KDM4EPOLBKMT2AMEN1
SCHEMBL109071 0.75 CA12 (0.42) L3MBTL1KDM4EPOLBKMT2AMEN1
SCHEMBL109836 0.74 ALOX5AP (0.40) L3MBTL1KDM4EPOLBKMT2AMEN1
SCHEMBL143872 0.73 KDM4E (0.46) L3MBTL1KDM4EPOLBALDH1A1HPGD
SCHEMBL31582715 0.73 KDM4E (0.54) L3MBTL1KDM4ENNMTPOLBKMT2A
SCHEMBL31264183 0.73 KDM4E (0.46) L3MBTL1KDM4EPOLBALDH1A1HPGD
SCHEMBL15359911 0.73 KDM4E (0.54) L3MBTL1KDM4ENNMTPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 L3MBTL1 2220/4885KDM4E 928/4885NNMT 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.